BioNexus Initiative: BioNexus Gene Lab Corp. announced the start of its regional deployment phase for VitaGuard™ Minimal Residual Disease (MRD) infrastructure, designed to support oncology monitoring workflows across key ASEAN healthcare hubs.

• Technical Focus: The VitaGuard™ platform aims to provide longitudinal cancer monitoring that is more affordable and scalable compared with existing legacy systems by leveraging proprietary cfDNA technology and high‑frequency sequencing.
• Strategic Aim: The deployment phase is intended to integrate the VitaGuard™ platform into routine clinical workflows, generate longitudinal datasets, and develop AI‑assisted oncology tools tailored to regional genomic profiles.
• Market Context: BioNexus positions the platform to challenge high‑cost oncology diagnostics and expand access to precision monitoring across Southeast Asia’s multi‑billion‑dollar healthcare market.

This summary is based on a press release by BioNexus Gene Lab Corp. reported on Taiwan News.